期刊文献+

恶性淋巴瘤的免疫治疗新进展 被引量:1

下载PDF
导出
摘要 随着恶性淋巴瘤的发病率逐渐上升,恶性淋巴瘤已经成为最常见的恶性肿瘤之一。免疫治疗已被公认为继手术、放疗、化疗之后第4种癌症治疗方法,并在恶性淋巴瘤患者的治疗中展现出越来越强的生存获益。恶性淋巴瘤的免疫治疗主要通过激发或阻断相关特异的免疫反应通路活化肿瘤细胞以杀灭肿瘤。本文综述了近几年来免疫调节剂,各靶点的免疫检查点药物,嵌合抗原受体基因修饰的T细胞(CART)继承性细胞,toll样受体激动剂等多种免疫治疗方法在恶性淋巴瘤患者当中的运用和目前存在的问题及免疫治疗以后的发展方向。
作者 李永强
出处 《广东医学》 CAS 2018年第S1期261-265,共5页 Guangdong Medical Journal
  • 相关文献

参考文献2

二级参考文献60

  • 1Sehn LH,Berry B,Chhanabhai M,et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Blood,2007,109:1857-1861.
  • 2Khouri IF,Saliba RM,Erwin WD,et al.Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma:12-year results[J].Blood,2012,119:6373-6378.
  • 3Bacher U,Klyuchnikov E,Le-Rademacher J,et al.Conditioning regimens for allotransplants for diffuse large B-cell lymphoma:myeloablative or reduced intensity?[J].Blood,2012,120:4256-4262.
  • 4van Besien K.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma[J].Curr Opin Oncol,2011,23:681-691.
  • 5Hoyos V,Savoldo B,Dotti G.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies[J].Haematologica,2012,97:1622-1631.
  • 6Kalos M,Levine BL,Porter DL,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Med,2011,3:95ra73.
  • 7Park TS,Rosenberg SA,Morgan RA.Treating cancer with genetically engineered T cells[J].Trends Biotechnol,2011,29:550-557.
  • 8Kowolik CM,Topp MS,Gonzalez S,et al.CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells[J].Cancer Res,2006,66:10995-11004.
  • 9SongDG,Ye Q,Carpenito C,et al.In vivo persistence,tumor localization,and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)[J].Cancer Res,2011,71:4617-4627.
  • 10Savoldo B,Ramos CA,Liu E,et al.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients[J].J Clin Invest,2011,121:1822-1826.

共引文献9

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部